Avalere’s examination of Medicare Part D plan tier placement of generic prescription drugs found that over time their percentage on generic tiers has declined from 65% in 2016 to 43% in 2022.
Alongside its Q4 results, the company announced an increase of its Prime membership monthly fee from $12.99 to $14.99 and annual membership from $119 to $139.
As part of the acquisition, Butterfly Equity and Andrew Abraham, Orgain’s founder and CEO, will retain significant minority ownership positions within the company.
